Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
about
Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignanciesAttenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 functionNitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusionsPegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats.Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicityLack of cell-cycle specific effects of tumor necrosis factor-alpha on tumor cells in vitro: implications for combination tumor therapy with doxorubicin.Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusionOne hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.Histamine combined with melphalan in isolated limb perfusion for the treatment of locally advanced soft tissue sarcomas: preclinical studies in rats.Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.The European approach to in-transit melanoma lesions.20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose mattersIsolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.Manipulation of the tumour-associated vasculature to improve tumour therapy.Solid tumor therapy: manipulation of the vasculature with TNF.Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculatureEffectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.The diverse roles of the TNF axis in cancer progression and metastasis.Tumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models.Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Immunocytokines: a review of molecules in clinical development for cancer therapy.Isolated limb infusion as a model to test new agents to treat metastatic melanoma.Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery.Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.Adjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness.Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics.Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity.Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ.Regional heterogeneity changes in DCE-MRI as response to isolated limb perfusion in experimental soft-tissue sarcomasIsolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma
P2860
Q28344330-2CA3CF87-0730-4D63-973B-147BD8A75AF4Q28728301-3CBEC8B0-B791-48AB-8168-788CF1532F1BQ33181229-EF7583C5-00D4-4631-8C69-E6206C15D9E9Q33183242-F0D4B219-1F13-48DA-A556-86D63422EA46Q33183585-21B59263-5EF7-4986-B70A-3C7E17944BC1Q33183884-6C271E72-9520-4AA8-B5D9-783493BC4565Q33186209-1A9352F8-9EE3-43AC-8242-33DC79184C64Q33209414-455D07C1-FB9D-4D2D-B92D-B200CE2D0B09Q33224018-E0D02AC6-7E68-4C5C-9297-631C063DF849Q33245795-2BD6F60E-9DA3-4700-A315-78366FA31F4DQ33263624-D0CAE6C9-186E-4A9F-98C3-66EE0D9A9673Q33309291-A3A1849B-163C-46E9-A94A-CE19AFB665D4Q33325343-4AB27576-879D-4DC9-B7F8-5FAF3B73148EQ33327121-6D4EA4D7-0A44-4DFD-A171-84A54D94B66DQ34006197-73336647-A50C-4065-A62A-190DEB3C8AF2Q34054797-E1D581AF-6E37-466E-8A60-19F1D8A186CAQ34662879-75705A6D-5198-4BB8-AC0D-09ECC273E27CQ35072789-EEFB3426-C489-4812-B58A-DEB30A76182EQ35142322-766BEEA0-0A06-4535-9BF3-A6B2BAC06436Q35646297-CB751200-111D-4761-A1DE-87C56CE8C7F7Q35690539-9634A894-0CF0-4798-BA89-1F907813A36FQ37130237-647AFBD8-D293-4BA3-BCEB-5B0AA8FE5E1DQ37474735-0CC9FF9B-FE4C-4FA1-B54E-8FFA9BA88DC7Q37506109-6B7689A6-9F14-41C9-A96B-CD7578F0BD1AQ37513298-4EC00BED-F1E3-457F-8C81-CC89B0B077EDQ38112578-504C29BA-4FC1-4D0D-9AF3-DB32E44D5339Q38132742-FED5F45E-78F8-43AE-B85E-D2B1A15D1111Q38187595-E59E41BA-8B80-4A2A-89AA-61EA6A47DCF9Q38740409-EF0B34B3-31AB-4D25-9317-E4503CE41D91Q38838678-7C618581-E19D-4AD7-9338-097C4F9B3F3AQ39735956-D23F9138-5AEA-43CA-B988-B2D5E04D6302Q39735980-B2E44FF1-984F-41FB-8BC2-380D6C945D7FQ41903537-C6F396A7-D417-4C98-9B0D-7B01FEDB9CDBQ43708720-F4508750-4144-4370-86A2-EECF470C1A94Q44763087-2693375F-BA82-4A50-BCEE-A8257958F9F9Q44862870-3C938AB4-2B48-4389-87E5-99CA8CB5946DQ47093975-48F1F37C-7042-4272-8523-8AF86E267692Q57719785-F7B2BAF8-47E5-49B9-802D-7202C267611DQ57911958-EFC236A0-CDE8-490E-B2B3-C3EEAC456873
P2860
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@ast
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@en
type
label
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@ast
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@en
prefLabel
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@ast
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@en
P2093
P356
P1476
Tumour necrosis factor alpha i ...... after isolated limb perfusion.
@en
P2093
Eggermont AM
de Boeck G
de Bruijn EA
de Wilt JH
ten Hagen TL
van Tiel ST
P2888
P304
P356
10.1054/BJOC.1999.1032
P407
P577
2000-03-01T00:00:00Z
P5875
P6179
1014627563